Bachem lays foundation for its largest peptides production facility

Bubendorf, Switzerland: – Bachem AG has commenced construction of its largest building to date, which will house the world’s most modern production facility for peptides and oligonucleotides, the complex molecules used in drugs to treat numerous diseases.

The laying of the foundation stone at Bachem’s headquarters site at Bubendorf marks the start of a projected two year construction project.

Center of excellence

The new building will significantly expand Bachem’s production capacities by 2024 and will reinforce Bubendorf’s credentials as a leading center of excellence for the manufacture of complex active pharmaceutical ingredients (APIs).

The five storey building will add to Bachem’s GMP-compliant production capacity for the manufacture of strictly regulated APIs to Bachem’s global network. In a first phase, it will provide up to 150 new highly skilled jobs. It also underline’s Bachem’s commitment to Switzerland as a primary location for its worldwide business.

Global expansion

The new building is part of a wider Bachem worldwide production expansion program in response to growing global demand. In Switzerland alone over CHF 150 million have been invested over the past five years at the Bubendorf and Vionnaz sites, with more than 400 new jobs created. The search for a third site in Switzerland is currently underway, as the limits of the Bubendorf site are reached.

The laying of the foundation stone coincided with Swiss National Future Day, on which young people visit Bachem every year to learn about working in pharmaceuticals and biotech. This year, young visitors were able to carry out simple chemistry experiments in the training laboratory under the supervision of apprentices and tour the production facilities.

Bachem CEO Thomas Meier commented: “I am delighted that we are commencing the construction of our largest production plant to date on National Future Day. Today has a special symbolism for Bachem. We are a company with a long-term mindset. Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have.”

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.

The company is listed on the SIX Swiss Exchange. For further information, visit the Bachem website.

Resources

Click on Bachem lays foundations for company’s largest production building on Swiss National Future Day to download original news release.
Click on Bachem History to learn more about the company’s back story
Click on Bachems News to see latest News & Events.